Downstream Pathways of Dulaglutide Effects

What downstream pathways explain dulaglutide's effects on glucagon secretion and gastric emptying?

Dulaglutide suppresses glucagon secretion through a paracrine somatostatin pathway mediated by SSTR2 receptors on pancreatic alpha cells, while the specific downstream pathways for gastric emptying delay remain unelucidated beyond GLP-1 receptor activation.

Abstract

Seven studies investigated dulaglutide’s mechanisms, though only three directly examined pathways for glucagon secretion or gastric emptying effects. For glucagon suppression, perfused pancreas experiments demonstrated that GLP-1 operates entirely through a paracrine somatostatin pathway: GLP-1 stimulates somatostatin secretion, which then acts through somatostatin receptor 2 (SSTR2) on pancreatic alpha cells to inhibit glucagon release. Blocking SSTR2 completely eliminated GLP-1’s glucagon-lowering effect, with glucagon secretion increasing by 118.8-162.9%. This inhibitory effect persists across glucose concentrations from 6.0 to 0.5 mmol/l, though how this mechanism avoids suppressing physiologically necessary glucagon responses to hypoglycemia in vivo remains unexplained.

In contrast, evidence for gastric emptying pathways came exclusively from computational models that incorporated gastric emptying delay as a GLP-1 receptor-mediated effect without specifying downstream cellular, neural, or smooth muscle mechanisms. The delay is most pronounced after initial dosing and diminishes with repeated administration, suggesting pharmacological tolerance distinct from the glucagon pathway, where GLP-1 receptor expression is maintained despite chronic exposure. This mechanistic asymmetry likely reflects methodological constraints: isolated perfused organs permit detailed study of paracrine islet signaling, while gastric emptying involves complex neuro-hormonal interactions not readily studied in reductionist experimental systems. Detailed mechanistic investigation of dulaglutide’s gastric emptying effects using ex vivo or in vivo approaches comparable to those applied for glucagon secretion has not been conducted.

Methods

We analyzed 7 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200
• Papers screened using: Primary Intervention, Target Outcomes, Mechanistic Focus, Study Design, Study System, Mechanistic Investigation, Study Type Quality
• n = 200 Papers screened out
• n = 193
• Papers included for extraction
• n = 7

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “What downstream pathways explain dulaglutide’s effects on glucagon secretion and gastric emptying?”

The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

• Primary Intervention: Does this study investigate dulaglutide as the primary intervention (not just as a comparator or control)?
• Target Outcomes: Does this study measure or investigate glucagon secretion, gastric emptying, or both as outcomes?
• Mechanistic Focus: Does this study examine, measure, or discuss downstream pathways, molecular mechanisms, signaling cascades, or mechanistic explanations?
• Study Design: Is this an experimental study (randomized controlled trial, non-randomized controlled trial, before-after study, or mechanistic study)?
• Study System: Is this study conducted in human subjects, animal models, or in vitro systems?
• Mechanistic Investigation: Does this study include mechanistic investigation beyond solely reporting clinical outcomes?
• Study Type Quality: Is this study something other than a case report, case series, editorial, or opinion piece?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Study Model

Extract the experimental model/system used to investigate dulaglutide’s mechanisms, including:

• Type of model (in vitro cell culture, animal model, human clinical study, computational model)
• Specific cell lines, animal species/strains, or patient populations
• Experimental conditions (doses, duration, co-treatments)
• Any limitations of the model for mechanistic investigation

Target Effects

Extract which of dulaglutide’s effects were investigated in this study:

• Glucagon secretion (specify if inhibition, stimulation, or modulation)
• Gastric emptying (specify if delay, acceleration, or modulation)
• Both effects studied
• Other related effects (insulin secretion, GLP-1R expression, etc.)
• Measurement methods used for each effect

Glucagon Pathways

Extract all downstream pathways, molecular mechanisms, and signaling cascades identified as explaining dulaglutide’s effects on glucagon secretion, including:

• Specific receptors involved (GLP-1R, somatostatin receptors, etc.)
• Key signaling molecules and pathways (cAMP, PKA, calcium, somatostatin, etc.)
• Cellular mechanisms (paracrine effects, direct effects on alpha cells, etc.)
• Intermediate factors or mediators
• Note if pathway is stimulatory or inhibitory for glucagon

Gastric Emptying Pathways

Extract all downstream pathways, molecular mechanisms, and signaling cascades identified as explaining dulaglutide’s effects on gastric emptying, including:

• Specific receptors and targets in the GI system
• Neural pathways (vagal, enteric nervous system)
• Hormonal mediators and signaling cascades
• Smooth muscle mechanisms
• Any pharmacokinetic implications of gastric emptying delay
• Note if pathway promotes delay or acceleration of emptying

Mechanistic Evidence

Extract the type and strength of experimental evidence supporting the identified pathways for dulaglutide’s effects on glucagon secretion and/or gastric emptying:

• Receptor antagonist/agonist studies
• Gene expression changes (qPCR, Western blot results)
• Functional assays (GSIS, hormone secretion, motility studies)
• Knockout/knockdown studies
• Pharmacological inhibitor studies
• Biomarker measurements
• Statistical significance and effect sizes where provided

Key Findings

Extract the main mechanistic conclusions about how dulaglutide affects glucagon secretion and/or gastric emptying, including:

• Novel pathway discoveries
• Confirmation or refutation of known mechanisms
• Quantitative relationships between dulaglutide and pathway components
• Time course of mechanistic effects
• Dose-response relationships for pathway activation
• Any unexpected or contradictory findings about mechanisms

Mechanistic Gaps

Extract any acknowledged limitations, uncertainties, or gaps in understanding dulaglutide’s mechanisms for glucagon secretion and gastric emptying effects, including:

• Unknown aspects of the pathways
• Conflicting evidence about mechanisms
• Study limitations that prevent mechanistic conclusions
• Need for further mechanistic investigation
• Differences between in vitro/animal and human mechanisms
• Unanswered questions about pathway specificity or redundancy

Results

Characteristics of included studies

Seven studies investigated dulaglutide’s mechanisms, though only three directly examined pathways for glucagon secretion or gastric emptying effects. The studies employed diverse methodological approaches ranging from perfused organ systems to computational modeling.

Downstream pathways for glucagon secretion

The most direct mechanistic evidence for dulaglutide’s glucagon-lowering effects came from a perfused mouse pancreas study that systematically tested the role of somatostatin. Ørgaard and Holst (2017) demonstrated that GLP-1 inhibited glucagon secretion by 27.0% at 6.0 mmol/l glucose, 37.1% at 1.5 mmol/l glucose, and 23.6% at 0.5 mmol/l glucose. These decreases were invariably accompanied by increases in somatostatin secretion of 286.8%, 158.7%, and 118.8%, respectively. When somatostatin receptor 2 (SSTR2) was specifically blocked with an antagonist, glucagon secretion increased by 118.8% at 1.5 mmol/l glucose and 162.9% at 6.0 mmol/l glucose, completely eliminating GLP-1’s inhibitory effect.

These findings establish that GLP-1’s glucagon-lowering effect operates entirely through a paracrine somatostatin pathway mediated by SSTR2 receptors, rather than through direct effects on pancreatic alpha cells. The pathway is inhibitory for glucagon secretion, with somatostatin serving as the critical intermediate mediator.

The computational QSP model developed by Bosch et al. (2021) incorporated these mechanistic principles, describing GLP-1’s inhibitory effect on glucagon production alongside a stimulatory effect of glucose-dependent insulinotropic peptide (GIP) on glucagon. The model confirmed that the GLP-1 pathway acts through GLP-1 receptors to produce an inhibitory effect on alpha cells, consistent with the somatostatin-mediated mechanism identified in the perfused pancreas experiments.

However, Ørgaard and Holst (2017) identified an important mechanistic gap: while their model preserved GLP-1’s inhibitory effect on glucagon at hypoglycemic glucose levels (0.5 mmol/l), this leaves unanswered how GLP-1 receptor agonists avoid suppressing the physiologically necessary glucagon response to hypoglycemia in vivo. The mechanism of GLP-1’s inhibitory effect on glucagon secretion remains heavily debated, with multiple theories including paracrine inhibition by insulin, direct action on alpha cells, and paracrine inhibition by somatostatin, though none are conclusively proven across all experimental contexts.

Downstream pathways for gastric emptying

Evidence for dulaglutide’s effects on gastric emptying came exclusively from computational modeling studies that integrated clinical pharmacology data. The QSP model characterized gastric emptying delay as occurring through GLP-1 receptor-mediated inhibition of glucose absorption. The model used an E_max function to describe GLP-1’s concentration-dependent inhibition of gastric emptying, resulting in delayed absorption that contributes to increased satiety and reduced food intake.

Posada et al. (2025) developed a population pharmacokinetic model demonstrating that dulaglutide’s gastric emptying delay is most pronounced after the initial dose and diminishes with subsequent doses. The delay was measured using scintigraphy and changes in acetaminophen pharmacokinetics. The PopPK model estimated exposure-dependent delays in gastric emptying, which were then integrated into PBPK models to predict effects on oral drug absorption. Importantly, the modeling demonstrated that dulaglutide at both 1.5 mg and 4.5 mg doses produces gastric emptying delay that has minimal clinically relevant effects on the pharmacokinetics of co-administered small molecules with high solubility and permeability.

Neither computational study detailed the specific receptors, neural pathways, hormonal mediators, or smooth muscle mechanisms underlying the gastric emptying effects. The models treated gastric emptying delay as a known consequence of GLP-1 receptor activation without mechanistic elaboration of the downstream signaling cascades in the gastrointestinal system.

Studies investigating alternative pathways

Four studies examined dulaglutide’s effects on other physiological systems through various molecular pathways, though these did not directly address glucagon secretion or gastric emptying mechanisms.

Lee et al. (2022) demonstrated that dulaglutide activates FAM3A signaling in hepatocytes to reduce lipid accumulation. When FAM3A was inhibited by siRNA, dulaglutide’s effects on triglyceride content and fatty acid oxidation were attenuated. The GLP-1R antagonist exendin-(9-39) reversed FAM3A expression increases caused by dulaglutide, confirming GLP-1R-dependence. However, the regulatory mechanisms by which dulaglutide activates FAM3A signaling remain to be fully elucidated, requiring additional investigation.

Darwish et al. (2023) identified GLP-1R/cAMP/PKA pathway activation as dulaglutide’s mechanism for antidepressant effects in a chronic stress model. While this pathway is relevant to cellular signaling more broadly, the study did not examine its role in glucagon or gastric emptying regulation.

El Mahdy et al. (2024) showed dulaglutide modulates TGF-β1, PI3K/AKT, and NF-κB pathways in the context of colonic inflammation, with dose-dependent reductions in TGF-β1 of 14.46%, 45.64%, and 58.12% at escalating doses. The study also demonstrated increases in GLP-1 levels with treatment, though these findings pertain to intestinal barrier function rather than glucagon or gastric motility.

Kimura et al. (2018) confirmed that chronic dulaglutide exposure does not downregulate GLP-1R expression in pancreatic β-cells. In diabetic mice, GLP-1R expression was augmented rather than reduced after 17 weeks of treatment, a finding that contradicts expectations of receptor downregulation with chronic ligand exposure. This preservation of receptor expression has implications for sustained glucagon inhibition, though the study focused on insulin secretion rather than glucagon pathways.

Synthesis

The available evidence reveals a substantial gap between mechanistic understanding of glucagon suppression versus gastric emptying delay. For glucagon secretion, experimental studies using perfused pancreas preparations have identified a specific paracrine pathway: GLP-1 stimulates somatostatin secretion from delta cells, which then acts through SSTR2 receptors on alpha cells to inhibit glucagon release. This mechanism is supported by complete reversal of glucagon inhibition when SSTR2 is blocked. The pathway operates across a wide glucose range, including hypoglycemic conditions in isolated preparations, though how this selectivity is maintained in vivo to preserve counter-regulatory responses remains unclear.

In contrast, gastric emptying effects are documented primarily through pharmacological observations and modeling rather than mechanistic pathway elucidation. Both computational models incorporated gastric emptying delay as a GLP-1R-mediated effect without specifying the downstream cellular or neural mechanisms. The delay shows pharmacological tolerance, being most pronounced after initial dosing, suggesting potential receptor desensitization or compensatory pathway activation that differs from the glucagon suppression mechanism, where receptor expression is maintained long-term.

The mechanistic asymmetry likely reflects methodological constraints: isolated perfused pancreas preparations permit detailed interrogation of paracrine signaling within islets, while gastric emptying involves complex interactions among enteric neurons, smooth muscle, and hormonal feedback that are difficult to study in reductionist systems. The QSP model acknowledged this limitation, noting insufficient data on meal composition effects and uniform assumptions about glucose absorption that may not reflect physiological variability. Neither modeling study incorporated neural regulation of gastric emptying, which may be critical for understanding the pathway’s clinical effects.

Future research should prioritize ex vivo or in vivo studies of gastric smooth muscle and enteric nervous system responses to dulaglutide to achieve mechanistic resolution comparable to that obtained for glucagon suppression. The role of somatostatin in glucose-mediated inhibition of glucagon secretion also requires further study to resolve conflicting theories about direct versus paracrine mechanisms. Understanding why GLP-1R expression is not downregulated despite chronic agonist exposure may inform why glucagon suppression persists while gastric emptying effects diminish over time.